发布求助
文献互助 智能选刊 最新文献

Trends in pharmacological sciences最新文献

筛选
英文 中文
Advisory Board and Contents 咨询委员会和内容
IF 13.8 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-05 DOI: 10.1016/s0165-6147(24)00171-8
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s0165-6147(24)00171-8","DOIUrl":"https://doi.org/10.1016/s0165-6147(24)00171-8","url":null,"abstract":"No Abstract","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":"55 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142203101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging chemophysiological diversity of gut microbiota metabolites. 肠道微生物群代谢物新出现的化学生理学多样性。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-10 DOI: 10.1016/j.tips.2024.07.006
Xiaorong Lin, Kaixin He, Zhen Gu, Xiaohui Zhao
{"title":"Emerging chemophysiological diversity of gut microbiota metabolites.","authors":"Xiaorong Lin, Kaixin He, Zhen Gu, Xiaohui Zhao","doi":"10.1016/j.tips.2024.07.006","DOIUrl":"10.1016/j.tips.2024.07.006","url":null,"abstract":"<p><p>Human physiology is profoundly influenced by the gut microbiota, which generates a wide array of metabolites. These microbiota-derived compounds serve as signaling molecules, interacting with various cellular targets in the gastrointestinal tract and distant organs, thereby impacting our immune, metabolic, and neurobehavioral systems. Recent advancements have unveiled unique physiological functions of diverse metabolites derived from tryptophan (Trp) and bile acids (BAs). This review highlights the emerging chemophysiological diversity of these metabolites and discusses the role of chemical and biological tools in analyzing and therapeutically manipulating microbial metabolism and host targets, with the aim of bridging the chemical diversity with physiological complexity in host-microbe molecular interactions.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"824-838"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structures reveal how SGLT inhibitors work. 结构揭示了 SGLT 抑制剂的工作原理。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1016/j.tips.2024.05.009
Zejian Sun, Wenhao Cui, Lei Chen
{"title":"Structures reveal how SGLT inhibitors work.","authors":"Zejian Sun, Wenhao Cui, Lei Chen","doi":"10.1016/j.tips.2024.05.009","DOIUrl":"10.1016/j.tips.2024.05.009","url":null,"abstract":"<p><p>Sodium glucose cotransporters (SGLTs) transport glucose against its concentration gradient by harnessing the electrochemical potential gradient of sodium ions. SGLT inhibitors are widely prescribed to treat diabetes and other conditions. Recent structural studies have uncovered how chemically diverse SGLT inhibitors bind and inhibit the transporter at the atomic level.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"760-763"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frontiers in CAR-T cell therapy for autoimmune diseases. CAR-T 细胞疗法治疗自身免疫性疾病的前沿。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-14 DOI: 10.1016/j.tips.2024.07.005
Yan-Ruide Li, Zibai Lyu, Yuning Chen, Ying Fang, Lili Yang
{"title":"Frontiers in CAR-T cell therapy for autoimmune diseases.","authors":"Yan-Ruide Li, Zibai Lyu, Yuning Chen, Ying Fang, Lili Yang","doi":"10.1016/j.tips.2024.07.005","DOIUrl":"10.1016/j.tips.2024.07.005","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has demonstrated significant success in treating cancers. The potential of CAR-T cells is now being explored in the context of autoimmune diseases. Recent clinical trials have shown sustained and profound elimination of autoreactive B cells by CAR-T cells, leading to promising autoimmune disease control with minimal safety concerns. These encouraging results have inspired further investigation into CAR-T cell applications for a broader range of autoimmune diseases and the development of advanced cell products with improved efficacy and safety. In this review, we discuss the mechanisms by which CAR-T cells target autoimmune conditions, summarize current preclinical models, and highlight ongoing clinical trials, including CAR-T therapy design, clinical outcomes, and challenges. Additionally, we discuss the limitations and future directions of CAR-T therapy in the treatment of autoimmune diseases.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"839-857"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting epigenetic enzymes for autism treatment. 针对表观遗传酶治疗自闭症。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-07-20 DOI: 10.1016/j.tips.2024.06.009
Zhen Yan
{"title":"Targeting epigenetic enzymes for autism treatment.","authors":"Zhen Yan","doi":"10.1016/j.tips.2024.06.009","DOIUrl":"10.1016/j.tips.2024.06.009","url":null,"abstract":"<p><p>Emerging preclinical autism research has shown the therapeutic promise of pharmacological inhibitors for epigenetic enzymes, such as histone deacetylases (HDAC), euchromatic histone methyltransferases (EHMT), and lysine-specific histone demethylase 1A (LSD1). These interventions restore gene expression, synaptic function, and behavioral performance in autism models, highlighting a new strategy for autism treatment.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"764-767"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'Living drugs' target CD70 in advanced renal tumors. 针对晚期肾肿瘤CD70的 "活药物
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.1016/j.tips.2024.07.002
Kilian Wagner, Peter J Siska
{"title":"'Living drugs' target CD70 in advanced renal tumors.","authors":"Kilian Wagner, Peter J Siska","doi":"10.1016/j.tips.2024.07.002","DOIUrl":"10.1016/j.tips.2024.07.002","url":null,"abstract":"<p><p>Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"757-759"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the STAT3 pathway with STAT3 degraders. 用 STAT3 降解剂靶向 STAT3 通路。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-07 DOI: 10.1016/j.tips.2024.07.003
Zhijie Wang, Xiaotong Liao, Haiqi He, Xia Guo, Jianjun Chen
{"title":"Targeting the STAT3 pathway with STAT3 degraders.","authors":"Zhijie Wang, Xiaotong Liao, Haiqi He, Xia Guo, Jianjun Chen","doi":"10.1016/j.tips.2024.07.003","DOIUrl":"10.1016/j.tips.2024.07.003","url":null,"abstract":"<p><p>Signal transducer and activator of transcription 3 (STAT3) has been widely considered as a therapeutic target for various diseases, especially tumors. Thus far, several STAT3 inhibitors have been advanced to clinical trials; however, the development of STAT3 inhibitors is hindered by numerous dilemmas. Fortunately, STAT3 degraders represent an alternative and promising strategy to block STAT3, attracting extensive research interest. Here, we analyze the recent advancements of STAT3 degraders, including proteolysis targeting chimeras (PROTACs) and small-molecule natural products, focusing on their structures, mechanisms, and biological activities. We discuss the potential opportunities and challenges for developing STAT3 degraders. It is hoped that this Review will provide insights into the discovery of potent STAT3-targeting drugs.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"811-823"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of hypoxia-inducible factor 1 in type 1 diabetes. 低氧诱导因子 1 在 1 型糖尿病中的作用。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-09 DOI: 10.1016/j.tips.2024.07.001
Raphael R Fagundes, Arnaud Zaldumbide, Cormac T Taylor
{"title":"Role of hypoxia-inducible factor 1 in type 1 diabetes.","authors":"Raphael R Fagundes, Arnaud Zaldumbide, Cormac T Taylor","doi":"10.1016/j.tips.2024.07.001","DOIUrl":"10.1016/j.tips.2024.07.001","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is a common autoimmune disease in which dysregulated glucose metabolism is a key feature. T1D is both poorly understood and in need of improved therapeutics. Hypoxia is frequently encountered in multiple tissues in T1D patients including the pancreas and sites of diabetic complications. Hypoxia-inducible factor (HIF)-1, a ubiquitous master regulator of the adaptive response to hypoxia, promotes glucose metabolism through transcriptional and non-transcriptional mechanisms and alters disease progression in multiple preclinical T1D models. However, how HIF-1 activation in β-cells of the pancreas and immune cells (two key cell types in T1D) ultimately affects disease progression remains controversial. We discuss recent advances in our understanding of the role of hypoxia/HIF-1-induced glycolysis in T1D and explore the possible use of drugs targeting this pathway as potential new therapeutics.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"798-810"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epitope landscape in autoimmune neurological disease and beyond. 自身免疫性神经疾病及其他疾病的表位图谱。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-23 DOI: 10.1016/j.tips.2024.07.007
Ivan Talucci, Hans M Maric
{"title":"Epitope landscape in autoimmune neurological disease and beyond.","authors":"Ivan Talucci, Hans M Maric","doi":"10.1016/j.tips.2024.07.007","DOIUrl":"10.1016/j.tips.2024.07.007","url":null,"abstract":"<p><p>Autoantibody binding has a central role in autoimmune diseases and has also been linked to cancer, infections, and behavioral disorders. Autoimmune neurological diseases remain misclassified also due to an incomplete understanding of the underlying disease-specific epitopes. Such epitopes are crucial for both pathology and diagnosis, but have historically been overlooked. Recent technological advancements have enabled the exploration of these epitopes, potentially opening novel clinical avenues. The precise identification of novel B and T cell epitopes and their autoreactivity has led to the discovery of autoantigen-specific biomarkers for patients at high risk of autoimmune neurological diseases. In this review, we propose utilizing newly available synthetic and cellular-surface display technologies and guide epitope-focused studies to unlock the potential of disease-specific epitopes for improving diagnosis and treatments. Additionally, we offer recommendations to guide emerging epitope-focused studies to broaden the current landscape.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"768-780"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges. 人类乳头瘤病毒相关癌症的纳米疗法：突破与挑战。
IF 13.9 1区 医学
Trends in pharmacological sciences Pub Date : 2024-09-01 Epub Date: 2024-08-24 DOI: 10.1016/j.tips.2024.07.004
Jéssica Lopes-Nunes, Paula A Oliveira, Carla Cruz
{"title":"Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges.","authors":"Jéssica Lopes-Nunes, Paula A Oliveira, Carla Cruz","doi":"10.1016/j.tips.2024.07.004","DOIUrl":"10.1016/j.tips.2024.07.004","url":null,"abstract":"<p><p>Human papillomaviruses (HPVs) are well-known causative agents of several cancers, yet selective therapies remain under investigation. Nanoparticles, for instance, are emerging as promising solutions to enhance the delivery and efficacy of therapeutic approaches. Despite the increasing number of nanotherapies offering advantages over current treatments, only one has advanced to clinical trials. This review highlights recent advances in nanotherapies for HPV-associated cancers, focusing on the delivery of small molecules, gene-targeted therapies, and vaccines. Some of the challenges faced in nanotherapies translation for clinical application are discussed, emphasizing the most used preclinical models that fail to accurately predict human responses, thereby hindering proper evaluation of nanotherapies. Additionally, we explore and discuss alternative promising new preclinical models that could pave the way for more effective nanotherapeutic evaluations.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"781-797"},"PeriodicalIF":13.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信